Interest-Based Ads

Attending scheduled doctor visits and taking your medication as prescribed are important. But owning your CML treatment journey is about getting involved and staying involved.

	Be informed and involved from day one    Understanding your Ph+ CML in chronic phase can help you take an active role in your treatment journey. Your doctor not only needs but wants to hear from you. National cancer sites, leukemia and CML organizations, and health care providers are also excellent information resources.
	Choose a doctor who works with you   A good patient-doctor relationship can strongly influence your CML journey. Consider choosing medical professionals who are experienced, compassionate, and listen to your concerns.
	Ask questions to align on a clear treatment plan    It’s OK not to know everything. Since it may be difficult to get the conversation going, here are some questions to help you get started: 1. What are some treatment goals I should know about?  2. What are the results of my latest blood work? 3. How is SCEMBLIX different from other medications for Ph+ CML in chronic phase? 4. What are the most serious and common side effects of SCEMBLIX? 5. How will I know if SCEMBLIX is working? 6. When might I expect to see results with SCEMBLIX?

Start on a treatment for Ph+ CML in chronic phase that may help you achieve your treatment goals   For more help getting the conversation started: Download Doctor Discussion Guide

Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; TKIs, tyrosine kinase inhibitors.

*SCEMBLIX was studied vs GLEEVEC^® (imatinib), TASIGNA^® (nilotinib), Sprycel ^® (dasatinib), and Bosulif ^® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.

^†Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

Next: FAQs & Glossary >